IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy

Nature Reviews Immunology

Volumn 18, Issue 9, 2018, Pages 545-558

  Ivashkiv, Lionel B ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE CELL; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL POLARITY; CELL REPROGRAMMING TECHNIQUE; EPIGENETICS; IMMUNITY; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LEUKOCYTE; MACROPHAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; NERVE CELL; NEUROLOGIC DISEASE; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; ANIMAL; BIOLOGICAL MODEL; GENETIC EPIGENESIS; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE ACTIVATION; METABOLISM; NEOPLASM;

ADAPTIVE IMMUNITY; ANIMALS; EPIGENESIS, GENETIC; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INFLAMMATION; INTERFERON-GAMMA; MACROPHAGE ACTIVATION; MACROPHAGES; METABOLIC DISEASES; MODELS, IMMUNOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85048729312     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/s41577-018-0029-z     Document Type: Review

References (123)

1. Hu, X. & Ivashkiv, L. B. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31, 539–550 (2009).
2. Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503–514 (2012).
3. Villarino, A. V., Kanno, Y. & O’Shea, J. J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat. Immunol. 18, 374–384 (2017).
4. Levy, D. E., Kessler, D. S., Pine, R., Reich, N. & Darnell, J. E. Jr. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev. 2, 383–393 (1988).
5. Levy, D. E., Lew, D. J., Decker, T., Kessler, D. S. & Darnell, J. E. Jr. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 9, 1105–1111 (1990).
6. Oyler-Yaniv, J. et al. Catch and release of cytokines mediated by tumor phosphatidylserine converts transient exposure into long-lived inflammation. Mol. Cell 66, 635–647.e7 (2017).
7. Kang, K. et al. Interferon-gamma represses M2 gene expression in human macrophages by disassembling enhancers bound by the transcription factor MAF. Immunity 47, 235–250.e4 (2017). This study reveals mechanisms by which IFNγ represses gene transcription and identifies the functional importance of IFNγ-repressed genes.
8. Langlais, D., Barreiro, L. B. & Gros, P. The macrophage IRF8/IRF1 regulome is required for protection against infections and is associated with chronic inflammation. J. Exp. Med. 213, 585–603 (2016).
9. Mancino, A. et al. A dual cis-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages. Genes Dev. 29, 394–408 (2015).
10. Bancerek, J. et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 38, 250–262 (2013).
11. Begitt, A. et al. STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. Nat. Immunol. 15, 168–176 (2014).
12. Majoros, A. et al. Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses. Front. Immunol. 8, 29 (2017).
13. Wienerroither, S. et al. Cooperative transcriptional activation of antimicrobial genes by STAT and NF-kappaB pathways by concerted recruitment of the mediator complex. Cell Rep. 12, 300–312 (2015).
14. Cheon, H., Yang, J. & Stark, G. R. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J. Interferon Cytokine Res. 31, 33–40 (2011).
15. Glass, C. K. & Natoli, G. Molecular control of activation and priming in macrophages. Nat. Immunol. 17, 26–33 (2016).
16. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20 (2014).
17. Piccolo, V. et al. Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk. Nat. Immunol. 18, 530–540 (2017). This study delineates mechanisms by which IFNγ and IL-4 oppose each other’s actions during macrophage polarization and shows the extent of plasticity of polarization phenotypes genome wide.
18. Qiao, Y. et al. Synergistic activation of inflammatory cytokine genes by interferon-gamma-induced chromatin remodeling and toll-like receptor signaling. Immunity 39, 454–469 (2013). This study identifies the epigenetic basis for synergistic transcriptional activation of inflammatory cytokine genes by IFNγ and TLR signalling.
19. Qiao, Y., Kang, K., Giannopoulou, E., Fang, C. & Ivashkiv, L. B. IFN-gamma induces histone 3 lysine 27 trimethylation in a small subset of promoters to stably silence gene expression in human macrophages. Cell Rep. 16, 3121–3129 (2016).
20. Chen, J. & Ivashkiv, L. B. IFN-gamma abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc. Natl Acad. Sci. USA 107, 19438–19443 (2010).
21. Hu, X., Chakravarty, S. D. & Ivashkiv, L. B. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol. Rev. 226, 41–56 (2008).
22. Karonitsch, T. et al. Interferon signals and monocytic sensitization of the interferon-gamma signaling pathway in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheumatism 64, 400–408 (2012).
23. Askenase, M. H. et al. Bone-marrow-resident NK cells prime monocytes for regulatory function during infection. Immunity 42, 1130–1142 (2015). This study clearly establishes that IFNγ-mediated priming occurs in vivo and is important for host defence against pathogens.
24. Leentjens, J. et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am. J. Respiratory Crit. Care Med. 186, 838–845 (2012). This study demonstrates that IFNγ reverses endotoxin tolerance in vivo in human subjects.
25. Cheng, S. C. et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat. Immunol. 17, 406–413 (2016).
26. Park, S. H. et al. Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat. Immunol. 18, 1104–1116 (2017).
27. Shi, L. et al. The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. PloS one 9, e93846 (2014).
28. Herrero, C. et al. Reprogramming of IL-10 activity and signaling by IFN-gamma. J. Immunol. 171, 5034–5041 (2003).
29. Monticelli, S. & Natoli, G. Short-term memory of danger signals and environmental stimuli in immune cells. Nat. Immunol. 14, 777–784 (2013).
30. Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972–978 (2007). This study introduces the concept of epigenetic regulation into the field of endotoxin tolerance.
31. Ivashkiv, L. B. Epigenetic regulation of macrophage polarization and function. Trends Immunol. 34, 216–223 (2013).
32. Smale, S. T., Tarakhovsky, A. & Natoli, G. Chromatin contributions to the regulation of innate immunity. Annu. Rev. Immunol. 32, 489–511 (2014).
33. Ostuni, R. et al. Latent enhancers activated by stimulation in differentiated cells. Cell 152, 157–171 (2013). This study demonstrates stable remodelling of chromatin at de novo enhancers induced by immune stimuli, including IFNγ, and helps pioneer the concept of short-term memory in macrophage responses.
34. Li, J. J. et al. IL-27/IFN-gamma induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages. J. Immunol. 185, 4401–4409 (2010).
35. Yoshimura, A., Ito, M., Chikuma, S., Akanuma, T. & Nakatsukasa, H. Negative regulation of cytokine signaling in immunity. Cold Spring Harb. Perspect. Biol. 10.1101/cshperspect.a028571 (2017).
36. Czimmerer, Z. et al. The transcription factor STAT6 mediates direct repression of inflammatory enhancers and limits activation of alternatively polarized macrophages. Immunity 48, 75–90.e76 (2018).
37. Biswas, S. K. & Lopez-Collazo, E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30, 475–487 (2009).
38. Ho, P. C., Tsui, Y. C., Feng, X., Greaves, D. R. & Wei, L. N. NF-kappaB-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance. Nat. Immunol. 13, 379–386 (2012).
39. Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).
40. Novakovic, B. et al. β-Glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354–1368.e14 (2016). This study extends the understanding of epigenetic mechanisms in innate immune training and establishes their importance in reversal of tolerance by training stimuli.
41. O’Neill, L. A., Kishton, R. J. & Rathmell, J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16, 553–565 (2016).
42. Hu, X. et al. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24, 563–574 (2006).
43. Meares, G. P., Qin, H., Liu, Y., Holdbrooks, A. T. & Benveniste, E. N. AMP-activated protein kinase restricts IFN-gamma signaling. J. Immunol. 190, 372–380 (2013).
44. Su, X. et al. Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nat. Immunol. 16, 838–849 (2015).
45. Deretic, V., Saitoh, T. & Akira, S. Autophagy in infection, inflammation and immunity. Nat. Rev. Immunol. 13, 722–737 (2013).
46. Van den Bossche, J. et al. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep. 17, 684–696 (2016).
47. Mills, E. L. et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell 167, 457–470.e13 (2016).
48. Ip, W. K. E., Hoshi, N., Shouval, D. S., Snapper, S. & Medzhitov, R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science 356, 513–519 (2017).
49. Greer, R. L. et al. Akkermansia muciniphila mediates negative effects of IFNgamma on glucose metabolism. Nat. Commun. 7, 13329 (2016).
50. Goldszmid, R. S. et al. NK cell-derived interferon-gamma orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 36, 1047–1059 (2012).
51. Weizman, O. E. et al. ILC1 confer early host protection at initial sites of viral infection. Cell 171, 795–808.e12 (2017).
52. Soudja, S. M., Ruiz, A. L., Marie, J. C. & Lauvau, G. Inflammatory monocytes activate memory CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion. Immunity 37, 549–562 (2012).
53. reg cells limit IFN-γ production to control macrophage accrual and phenotype during skeletal muscle regeneration. Proc. Natl Acad. Sci. USA 115, E2585–E2593 (2018).
54. Moro, K. et al. Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat. Immunol. 17, 76–86 (2016).
55. Pachlopnik Schmid, J. et al. Inherited defects in lymphocyte cytotoxic activity. Immunol. Rev. 235, 10–23 (2010).
56. Canna, S. W. Editorial: interferon-gamma: friend or foe in systemic juvenile idiopathic arthritis and adult-onset Still’s Disease? Arthritis Rheumatol. 66, 1072–1076 (2014).
57. Avau, A. et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund’s complete adjuvant: regulation by interferon-gamma. Arthritis Rheumatol. 66, 1340–1351 (2014).
58. Canna, S. W. & Goldbach-Mansky, R. New monogenic autoinflammatory diseases—a clinical overview. Seminars Immunopathol. 37, 387–394 (2015).
59. Liu, Y. et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheumatism 64, 895–907 (2012).
60. Reinhardt, R. L. et al. A novel model for IFN-gamma-mediated autoinflammatory syndromes. J. Immunol. 194, 2358–2368 (2015).
61. Domeier, P. P. et al. IFN-gamma receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J. Exp. Med. 213, 715–732 (2016).
62. Jackson, S. W. et al. B cell IFN-gamma receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J. Exp. Med. 213, 733–750 (2016).
63. Lee, S. K. et al. Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 37, 880–892 (2012).
64. Manni, M. et al. Regulation of age-associated B cells by IRF5 in systemic autoimmunity. Nat. Immunol. 19, 407–419 (2018).
65. Chiche, L. et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 66, 1583–1595 (2014).
66. Hall, J. C. et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc. Natl Acad. Sci. USA 109, 17609–17614 (2012).
67. Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014).
68. Welcher, A. A. et al. Blockade of interferon-gamma normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 67, 2713–2722 (2015).
69. Werth, V. P. et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 69, 1028–1034 (2017).
70. Touma, Z. & Gladman, D. D. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci. Med. 4, e000239 (2017).
71. Chong, W. P. et al. NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-gamma-IL-27 axis. J. Exp. Med. 212, 1739–1752 (2015).
72. Koblish, H. K., Hunter, C. A., Wysocka, M., Trinchieri, G. & Lee, W. M. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med. 188, 1603–1610 (1998).
73. Tarrant, T. K. et al. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J. Exp. Med. 189, 219–230 (1999).
74. Hall, A. O. et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 37, 511–523 (2012).
75. Levine, A. G. et al. Stability and function of regulatory T cells expressing the transcription factor T-bet. Nature 546, 421–425 (2017).
76. Newson, J. et al. Inflammatory resolution triggers a prolonged phase of immune suppression through COX-1/mPGES-1-derived prostaglandin E2. Cell Rep. 20, 3162–3175 (2017).
77. Vannella, K. M. & Wynn, T. A. Mechanisms of organ injury and repair by macrophages. Annu. Rev. Physiol. 79, 593–617 (2017).
78. McLaren, J. E. & Ramji, D. P. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 20, 125–135 (2009).
79. Liu, W. et al. dNK derived IFN-gamma mediates VSMC migration and apoptosis via the induction of LncRNA MEG3: a role in uterovascular transformation. Placenta 50, 32–39 (2017).
80. Kataru, R. P. et al. T lymphocytes negatively regulate lymph node lymphatic vessel formation. Immunity 34, 96–107 (2011). This study establishes a new function for IFNγ in the regulation of lymphatic vessels and lymph node function by acting directly on tissue cells.
81. Harismendy, O. et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 470, 264–268 (2011).
82. Tabas, I. & Lichtman, A. H. Monocyte-macrophages and T cells in atherosclerosis. Immunity 47, 621–634 (2017).
83. Odegaard, J. I. & Chawla, A. Type 2 responses at the interface between immunity and fat metabolism. Curr. Opin. Immunol. 36, 67–72 (2015).
84. Wensveen, F. M. et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat. Immunol. 16, 376–385 (2015).
85. O’Sullivan, T. E. et al. Adipose-resident group 1 innate lymphoid cells promote obesity-associated insulin resistance. Immunity 45, 428–441 (2016).
86. Molofsky, A. B. et al. Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 43, 161–174 (2015).
87. Rajbhandari, P. et al. IL-10 signaling remodels adipose chromatin architecture to limit thermogenesis and energy expenditure. Cell 172, 218–233.e17 (2018).
88. Herz, J., Filiano, A. J., Smith, A., Yogev, N. & Kipnis, J. Myeloid cells in the central nervous system. Immunity 46, 943–956 (2017).
89. Ransohoff, R. M. How neuroinflammation contributes to neurodegeneration. Science 353, 777–783 (2016).
90. Salter, M. W. & Stevens, B. Microglia emerge as central players in brain disease. Nat.Med. 23, 1018–1027 (2017).
91. Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell 170, 649–663.e13 (2017).
92. Baruch, K. et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat. Med. 22, 135–137 (2016).
93. Kreutzfeldt, M. et al. Neuroprotective intervention by interferon-gamma blockade prevents CD8+ T cell-mediated dendrite and synapse loss. J. Exp. Med. 210, 2087–2103 (2013).
94. Sun, G. et al. gammadelta T cells provide the early source of IFN-gamma to aggravate lesions in spinal cord injury. J. Exp. Med. 215, 521–535 (2018).
95. Filiano, A. J. et al. Unexpected role of interferon-gamma in regulating neuronal connectivity and social behaviour. Nature 535, 425–429 (2016). This study introduces the importance of the direct action of IFNγ on neurons under physiologic conditions and delineates the importance of IFNγ for neuronal function and social behaviours.
96. Derecki, N. C. et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 207, 1067–1080 (2010).
97. Oetjen, L. K. et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 171, 217–228.e13 (2017).
98. Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836–848 (2006).
99. Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer 16, 131–144 (2016).
100. Glasner, A. et al. NKp46 receptor-mediated interferon-gamma production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis. Immunity 48, 396–398 (2018).
101. Callahan, M. K., Postow, M. A. & Wolchok, J. D. Targeting T cell co-receptors for cancer therapy. Immunity 44, 1069–1078 (2016).
102. Minn, A. J. & Wherry, E. J. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 165, 272–275 (2016).
103. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
104. Fu, T., He, Q. & Sharma, P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 71, 5445–5454 (2011).
105. Liakou, C. I. et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987–14992 (2008).
106. Peng, W. et al. PD-1 blockade enhances T cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 72, 5209–5218 (2012).
107. Shi, L. Z. et al. Interdependent IL-7 and IFN-gamma signalling in T cell controls tumour eradication by combined alpha-CTLA-4+alpha-PD-1 therapy. Nat. Commun. 7, 12335 (2016).
108. Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404.e9 (2016). Together with references 109–112, this study establishes the pivotal role of IFNγ pathways in the efficacy of immune checkpoint blockade therapy for cancers.
109. Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017).
110. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
111. Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413–418 (2017).
112. Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537–542 (2017).
113. Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).
114. Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189–1201 (2017).
115. Nirschl, C. J. et al. IFNgamma-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell 170, 127–141.e15 (2017).
116. Zaidi, M. R. et al. Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. Nature 469, 548–553 (2011).
117. Kammertoens, T. et al. Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature 545, 98–102 (2017).
118. Tian, L. et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544, 250–254 (2017).
119. Overacre-Delgoffe, A. E. et al. Interferon-gamma drives Treg fragility to promote anti-tumor immunity. Cell 169, 1130–1141.e11 (2017).
120. Hannesdottir, L. et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur. J. Immunol. 43, 2718–2729 (2013).
121. Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142–7147 (2011).
122. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
123. Wang, W. et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165, 1092–1105 (2016).